These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 28902178

  • 21. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
    Lai YD, Wu YY, Tsai YJ, Tsai YS, Lin YY, Lai SL, Huang CY, Lok YY, Hu CY, Lai JS.
    Int J Mol Sci; 2016 Feb 05; 17(2):214. PubMed ID: 26861297
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
    Basilico C, Modica C, Maione F, Vigna E, Comoglio PM.
    Int J Cancer; 2018 Oct 01; 143(7):1774-1785. PubMed ID: 29693242
    [Abstract] [Full Text] [Related]

  • 24. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 25. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
    Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE.
    Cancer Res; 2010 Jan 15; 70(2):639-45. PubMed ID: 20068147
    [Abstract] [Full Text] [Related]

  • 26. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 15; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 27. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY, Jiao DM, Wu YQ, Chen J, Wang J, Tang XL, Mou H, Hu HZ, Song J, Yan J, Wu LJ, Chen J, Wang Z.
    Oncotarget; 2016 Apr 05; 7(14):18247-61. PubMed ID: 26919096
    [Abstract] [Full Text] [Related]

  • 28. Preclinical development of a humanized neutralizing antibody targeting HGF.
    Kim H, Hong SH, Kim JY, Kim IC, Park YW, Lee SJ, Song SW, Kim JJ, Park G, Kim TM, Kim YH, Park JB, Chung J, Kim IH.
    Exp Mol Med; 2017 Mar 24; 49(3):e309. PubMed ID: 28336956
    [Abstract] [Full Text] [Related]

  • 29. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
    Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A, Shitara K.
    Prostate; 2008 May 01; 68(6):640-50. PubMed ID: 18213631
    [Abstract] [Full Text] [Related]

  • 30. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A.
    Clin Cancer Res; 2013 Jun 01; 19(11):2941-51. PubMed ID: 23553846
    [Abstract] [Full Text] [Related]

  • 31. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Jun 01; 36(3):104-112. PubMed ID: 28504613
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.
    Clin Cancer Res; 2010 Aug 01; 16(15):3933-43. PubMed ID: 20628031
    [Abstract] [Full Text] [Related]

  • 33. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G, Salnikov AV, Lüttgau S, Herr I, Anderl J, Faulstich H.
    J Natl Cancer Inst; 2012 Apr 18; 104(8):622-34. PubMed ID: 22457476
    [Abstract] [Full Text] [Related]

  • 34. SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity.
    Zhang HT, Wang L, Ai J, Chen Y, He CX, Ji YC, Huang M, Yang JY, Zhang A, Ding J, Geng MY.
    J Pharmacol Exp Ther; 2014 Jul 18; 350(1):36-45. PubMed ID: 24741075
    [Abstract] [Full Text] [Related]

  • 35. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, Rø TB.
    Eur J Haematol; 2013 Nov 18; 91(5):399-410. PubMed ID: 23952536
    [Abstract] [Full Text] [Related]

  • 36. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.
    Am J Pathol; 2012 Sep 18; 181(3):1034-43. PubMed ID: 22789825
    [Abstract] [Full Text] [Related]

  • 37. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, Zhang L, Shang C, Chen Y.
    Clin Cancer Res; 2014 Jun 01; 20(11):2959-70. PubMed ID: 24700742
    [Abstract] [Full Text] [Related]

  • 38. A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice.
    de Ridder GG, Ray R, Pizzo SV.
    Melanoma Res; 2012 Jun 01; 22(3):225-35. PubMed ID: 22495669
    [Abstract] [Full Text] [Related]

  • 39. Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies.
    Qamsari ES, Sharifzadeh Z, Bagheri S, Riazi-Rad F, Younesi V, Abolhassani M, Ghaderi SS, Baradaran B, Somi MH, Yousefi M.
    J Immunotoxicol; 2017 Dec 01; 14(1):23-30. PubMed ID: 28090795
    [Abstract] [Full Text] [Related]

  • 40. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
    Lu J, Li G, He K, Jiang W, Xu C, Li Z, Wang H, Wang W, Wang H, Teng X, Teng L.
    J Transl Med; 2015 Feb 01; 13():42. PubMed ID: 25638174
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.